|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **First-time AP**n=59 | **Future ARP**n=14 | **Single AP episode**n=45 | **P** |
| **Moderate-severe AP, n (%)** | 8 (13.6%) | 1 (7.1%) | 7 (15.6%) | 0.67 |
|  |  |  |  |  |
| **Demographics** |  |  |  |  |
|  **-males, n (%)** | 34 (57.6%) | 9 (64.3%) | 25 (55.6%) | 0.56 |
|  **-age at 1st episode, years** | 11.3 (5.9-15.4) | 12.6 (7.4-15.6) | 11.0 (5.7-15.3) | 0.42 |
|  **-weight percentile for age & sex** | 54 (17-74) | 64 (55-68) | 47 (14-80) | 0.51 |
|  |  |  |  |  |
|  |  |  |  |  |
| **Admission laboratory results** |  |  |  |  |
| **CBC** |  |  |  |  |
|  **-hemoglobin, g/dL** | 12.9 (1.7) | 12.9 (1.5) | 12.9 (1.8) | 0.77 |
|  **-hematocrit, %** | 38.4 (5.0) | 38.7 (4.7) | 38.3 (5.2) | 0.95 |
|  **-WBC, 109/L** | 11.4 (8.1-15.0) | 12.5 (8.6-18.5) | 11 (7.8-15.0) | 0.24 |
|  **-platelet, 109/L** | 324 (265-399) | 342 (269-366) | 321 (259-420) | 0.93 |
|  |  |  |  |  |
| **Biochemistry** |  |  |  |  |
|  **-glucose, mg/dL** | 105 (95-122) | 105 (97-113) | 105 (93-122) | 0.78 |
|  **-sodium, mmol/L** | 138 (136-140) | 138 (136-141) | 138 (136-139) | 0.90 |
|  **-calcium, mg/dL** | 9.3 (0.5) | 9.5 (0.5) | 9.2 (0.5) | 0.06 |
|  **-chloride, mmol/L** | 102.6 (3.7) | 103.1 (4.3) | 102.5 (3.6) | 0.62 |
|  **-creatinine, mg/dL** | 0.7 (0.6-0.8) | 0.7 (0.7-0.8) | 0.7 (0.6-0.8) | 0.32 |
|  **-BUN, mg/dL** | 11 (9-13) | 10 (9-13) | 11 (9-13) | 0.99 |
|  **-albumin, g/L** | 42.5 (4.9) | 44.7 (4.1)  | 42 (5.0) | 0.09 |
|  **-ALT, U/L** | 18 (11-40) | 18 (9-23) | 17 (11-49) | 0.14 |
|  **-gGT, U/L** | 13 (8-50) | 13 (8-16) | 12 (8-61) | 0.22 |
|  **-total cholesterol, mg/dL**  | 143 (129-170) | 146 (135-161) | 143 (126-170) | 0.71 |
|  **-triglycerides, mg/dL** | 81 (53-122) | 73 (54-85) | 104 (52-129) | 0.57 |
|  **-amylase, U/L** | 485 (150-918) | 609 (500-1940) | 290 (137-869) | 0.19 |
|  **-lipase, U/L** | 485 (191-1129) | 477 (209-1221) | 500 (186-1036) | 0.65 |
|  |  |  |  |  |
| **Pancreatic imaging (n=90), n (%)** |  | n=12 | n=41 |  |
|  **-non-specific inflammation\*** | 30 (56.6%) | 10 (83.3%) | 20 (48.8%) | **0.03** |
|  **-peripancreatic fluid collection** | 7 (13.2%) | 1 (8.3%) | 6 (14.6%) | 1.0 |
|  **-pancreatic necrosis** | 2 (3.8%) | 0 | 2 (4.9%) | 1.0 |
|  **-cholelithiasis** | 7 (13.2%) | 0 | 7 (17.1%) | 0.33 |
|  **-normal imaging** | 23 (43.4%) | 2 (16.7%) | 21 (51.2%) | 0.06 |
|  |  |  |  |  |
| **Clinical course** |  |  |  |  |
| **symptoms duration****prior to admission, days** | 2 (1-5) | 2 (1-4) | 1 (1-5) | 0.77 |
| **Treatment, n (%)** |  |  |  |  |
|  **-NGT feeding** | 12 (20.3%) | 2 (14.3%) | 10 (22.2%) | 0.71 |
|  **-TPN** | 8 (13.6%) | 4 (28.6%) | 4 (8.9%) | 0.08 |
|  **-Antibiotics** | 19 (32.2%) | 4 (28.6%) | 15 (33.3%) | 1.0 |
| **Interventions, n (%)** |  |  |  |  |
|  **-all** | 3 (5.1%) | 0 | 3 (6.7%) | 1.0 |
|  **-ERCP** | 0 | 0 | 0 | 1.0 |
|  **-ERCP + stenting** | 1 (1.7%) | 0 | 1 (2.2%) | 1.0 |
|  **-CT guided collection drainage** | 0 | 0 | 0 | 1.0 |
|  **-endoscopic cyst drainage** | 1 (1.7%) | 0 | 1 (2.2%) | 1.0 |
|  **-surgery** | 1 (1.7%) | 0 | 1 (2.2%) | 1.0 |
|  |  |  |  |  |
| **Analgesics, maximal class (n=86), n (%)** |  | n=10 | n=31 |  |
|  **-non-opioids** | 36 (87.8%) | 10 (100%) | 26 (83.9%) | 0.43 |
|  **-mild opioids** | 1 (2.4%) | 0 | 1 (3.2%) | 1.0 |
|  **-strong opioids** | 4 (9.8%) | 0 | 4 (12.9%) | 0.56 |
|  **-any opioids** | 5 (12.2%) | 0 | 5 (16.1%) | 0.31 |
|  **-no analgesics** | 0 | 0 | 0 | 1.0 |
|  |  |  |  |  |
| **Hospitalization duration, days** | 6 (4-8) | 6 (4-8) | 6 (4-8) | 0.89 |
|  |  |  |  |  |
| **Presumed diagnosis, n (%)** |  |  |  |  |
|  **-anatomic anomaly** | 3 (5.1%) | 2 (14.3%) | 1 (2.2%) | 0.14 |
|  **-medication associated** | 12 (20.3%) | 1 (7.1%) | 11 (24.4%) | 0.26 |
|  **-cholelithiasis** | 6 (10.2%) | 0 | 6 (13.3%) | 0.32 |
|  **-post-ERCP** | 1 (1.7%) | 0 | 1 (2.2%) | 1.0 |
|  **-trauma** | 3 (5.1%) | 1 (7.1%) | 2 (4.4%) | 0.56 |
|  **-idiopathic** | 34 (57.6%) | 10 (71.4%) | 24 (53.3%) | 0.23 |

**Supplementary Table 3. Demographics and clinical course of patients with sentinel AP episodes- single vs. ARP patients.**

Values are presented as number of patients (%), means (standard deviation), median (25-75% interquartile range). Student t-test and Wilcoxon test were used for continuous variables, and categorical variables were compared by the Pearson χ2-test or Fisher Exact test; all tests were done using 2 sided tails with a confidence interval of 95%. AP- acute pancreatitis; ARP- acute recurrent pancreatitis; WBC- white blood cells; BUN- blood urea nitrogen; ALT- alanine transaminase; gGT- gamma-glutamiltransferase; CRP- C reactive protein; NGT- nasogastric tube; ERCP- endoscopic retrograde cholangio-pancreatography.

\*non-specific inflammation findings- including pancreatic edema, pancreatic enlargement and/or small amount of peri-pancreatic fluid.